Logo for Absci Corporation

Absci Investor Relations Material

Latest events

Logo for Absci Corporation

Q2 2024

Absci
Logo for Absci

Q2 2024

14 Aug, 2024
Logo for Absci

Q1 2024

14 May, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Absci Corporation

Access all reports
Absci Corporation operates as a generative AI drug creation company, focusing on revolutionizing the process of biologics drug discovery. Leveraging an integrated drug creation platform, Absci identifies novel drug targets and creates biotherapeutic candidates, shifting from traditional drug discovery to drug creation. This approach enables the design of de novo antibodies directly on computers, potentially reducing the development time for new drug leads and increasing their probability of success. The company's platform combines artificial intelligence with synthetic biology, allowing the construction and testing of millions of AI designs weekly. This innovative process results in wet lab-validated biologic-based therapeutics in a significantly shortened timeframe, aiming to address the challenges of traditionally high failure rates and lengthy development times in biologics drug discovery. The company is headquartered in Vancouver, Washington, and its shares are listed on the Nasdaq.